pharmaphorum

APRIL 15, 2015

Regardless of the colour of the next UK government that emerges as a result of the May election, the £30-£50bn NHS budget chasm is the abyss that all the parties fear in respect of its thereat to quality health service delivery and re-election. With political backs to the abyss, no hostages will be taken. It is not unrealistic to expect a well co-ordinated and concerted offence by politicians and patient organisations alike on industry pricing of innovative speciality and rare diseases medicines

Marketing 52

Marketing Medicine Drugs 52

Research Ethics Blog

APRIL 17, 2015

This is a must-read for anyone interested in the ethics of drug development and clinical trials. It explores how genuinely bad behaviour on the part of pharmaceutical companies can lead to overreaction by journalists and the public, sometimes with tragic consequences. By Matthew Herper, writing for Forbes.com: How Marketing And Media Muddled The Truth About The Heart Drug Vytorin.

Clinical Trials 40

Clinical Trials Clinical Trials Marketing Drugs 40

Research Ethics Blog

APRIL 14, 2015

From The State Journal-Register (Springfield, IL). Patient freedom, ethics at the heart of ‘Right to Try’ push in Illinois. Some doctors worry that an effort to grant terminally ill people more access to unproven drugs might offer them false hope or even be harmful, but advocates for a “right to try” say patients should have more opportunities for treatments that could extend their lives.

Drugs 40

Drugs Doctors Doctor 40

Research Ethics Blog

APRIL 12, 2015

In this newspaper editorial, a former governor of Minnesota says that the current president of the University of Minnesota needs to go, because of how he has mishandled controversy over research ethics at the university: Markingson case: University of Minnesota can’t regain trust under current leadership. …During his first year at the university, Kaler had to make a major decision.

Research 40

Research Clinical Research 40

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Research Ethics Blog

APRIL 6, 2015

This story is pretty much a ‘perfect storm’ of research ethics problems: international research, on vulnerable populations (orphans, prisoners and mental health patients), lack of consent, and questionable institutional responsibility for the actions of now-dead researchers. From The Guardian: Guatemalans deliberately infected with STDs sue Johns Hopkins University for $1bn.

Research 40

Research 40

Research Ethics Blog

APRIL 11, 2015

Here are three related items to bring to your attention: On the blog of Policy Options magazine, here’s a very good piece by our pal Tim Caulfield, called Homeopathy and the ethics of researching magic. And via the same outlet, here’s my piece in which I partly disagree with Tim: Homeopathy and Research Ethics. And just recently, An anonymous Canadian foundation grants $3 million to study naturopathic oncology.

Medicine 40

Medicine Research 40